426c.Mod.Core-C4b vaccine(National Institute of Allergy and Infectious Diseases)(426c.Mod.Core-C4b vaccine(National Institute of Allergy and Infectious Diseases))

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

免疫系统疾病感染泌尿生殖系统疾病

在研适应症

HIV感染

非在研适应症-

原研机构

National Institute of Allergy & Infectious Diseases

在研机构

HIV Vaccine Trials NetworkNational Institute of Allergy & Infectious Diseases

非在研机构-

权益机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 426c.Mod.Core-C4b vaccine(National Institute of Allergy and Infectious Diseases) 相关的临床试验

NCT06613789

/ Not yet recruiting临床1期IIT

A Partially Randomized Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of 426c.Mod.Core-C4b Vaccine Adjuvanted With 3M-052-AF + Alum in Infants With Perinatal HIV Exposure Who Are Without HIV at Birth

The purpose of this study is to evaluate the safety and immunogenicity of 426c.Mod.Core-C4b vaccine adjuvanted with 3M-052-AF + Alum in infants with perinatal HIV exposure who are without HIV at birth

开始日期2025-10-13

申办/合作机构

HIV Vaccine Trials Network

[+3]

NCT06796686

/ Recruiting临床1期IIT

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health

This is a partially randomized, open-label phase 1 study to evaluate the safety and immunogenicity of a priming regimen of 426c.Mod.Core-C4b adjuvanted with 3M-052 AF + Alum followed by boosts with HxB2.WT.Core-C4b adjuvanted with 3M-052 AF + Alum.
The primary hypothesis is that the boosting with HxB2.WT.Core-C4b adjuvanted with 3M-052 AF + Alum will further mature broadly neutralizing antibody (bnAb)-precursor B-cell lineages elicited by 426c.Mod.Core-C4b adjuvanted with 3M-052 AF + Alum.
426c.Mod.Core-C4b adjuvanted with 3M-052 AF + Alum has been tested in HVTN 301 previously, whereas the HxB2.WT.Core-C4b will be first-in-human (FIH).

开始日期2025-03-17

申办/合作机构

National Institute of Allergy & Infectious Diseases

NCT06006546

/ Recruiting临床1期IIT

426c.Mod.Core-C4b Adjuvanted With 3M-052-AF + Alum Immunization in Combination With an Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of VRC01-lineage Antibodies

This is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).

开始日期2024-01-03

申办/合作机构

National Institute of Allergy & Infectious Diseases

100 项与 426c.Mod.Core-C4b vaccine(National Institute of Allergy and Infectious Diseases) 相关的临床结果

登录后查看更多信息

100 项与 426c.Mod.Core-C4b vaccine(National Institute of Allergy and Infectious Diseases) 相关的转化医学

登录后查看更多信息

100 项与 426c.Mod.Core-C4b vaccine(National Institute of Allergy and Infectious Diseases) 相关的专利（医药）

登录后查看更多信息

100 项与 426c.Mod.Core-C4b vaccine(National Institute of Allergy and Infectious Diseases) 相关的药物交易

登录后查看更多信息